Targeted Approaches to T-Cell Lymphoma

被引:1
|
作者
Harrop, Sean [1 ]
Abeyakoon, Chathuri [2 ]
Van der Weyden, Carrie [1 ]
Prince, H. Miles [1 ,3 ,4 ]
机构
[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia
[2] Monash Hlth, Melbourne, Vic 3168, Australia
[3] Epworth Healthcare, Melbourne, Vic 3002, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3000, Australia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 06期
关键词
novel agents; monoclonal antibodies; immunotherapy; NON-HODGKIN-LYMPHOMA; BRENTUXIMAB VEDOTIN; PHASE-II; MYCOSIS-FUNGOIDES; OPEN-LABEL; CD30; EXPRESSION; SEZARY-SYNDROME; PI3K-DELTA; GAMMA INHIBITOR; MONOCLONAL-ANTIBODY; PHYSICIANS CHOICE;
D O I
10.3390/jpm11060481
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma
    Yap, Daniel Ren Yi
    Lim, Jing Quan
    Huang, Dachuan
    Ong, Choon Kiat
    Chan, Jason Yongsheng
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] New Targeted Treatments for Cutaneous T-cell Lymphomas
    Bagot, Martine
    INDIAN JOURNAL OF DERMATOLOGY, 2017, 62 (02) : 142 - 145
  • [33] Advances in the pharmacological management of cutaneous T-cell lymphoma
    Roccuzzo, Gabriele
    Roggo, Andrea
    Ramelyte, Egle
    Marchisio, Sara
    Astrua, Chiara
    Ribero, Simone
    Scarisbrick, Julia
    Fava, Paolo
    Quaglino, Pietro
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, : 885 - 894
  • [35] Development of new agents for peripheral T-cell lymphoma
    Ito, Yuta
    Makita, Shinichi
    Tobinai, Kensei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (03) : 197 - 209
  • [36] Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma
    Moskowitz, Alison J.
    JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (03) : 137 - 144
  • [37] Advances in Frontline Management of Peripheral T-cell Lymphoma
    Abeyakoon, Chathuri
    van der Weyden, Carrie
    Harrop, Sean
    Khot, Amit
    Dickinson, Michael
    Yannakou, Costas K.
    Prince, H. Miles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06) : 368 - 378
  • [38] Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma
    Licht, Philipp
    Mailaender, Volker
    CELLS, 2022, 11 (03)
  • [39] Update on T-Cell Lymphoma Epidemiology
    Chen, Jane J.
    Tokumori, Franco Castillo
    Del Guzzo, Christina
    Kim, Jeanyoung
    Ruan, Jia
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2024, 19 (03) : 93 - 103
  • [40] Emerging drugs for T-cell lymphoma
    Dickinson, Michael
    Prince, Henry Miles
    EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (02) : 201 - 213